Anemia and brain oxygen after severe traumatic brain injury

Mauro Oddo · Joshua M. Levine · Monisha Kumar · Katia Iglesias · Suzanne Frangos · Eileen Maloney-Wilensky · Peter D. Le Roux

Abstract Purpose: To investigate the relationship between hemoglobin (Hgb) and brain tissue oxygen tension (PbtO₂) after severe traumatic brain injury (TBI) and to examine its impact on outcome. Methods: This was a retrospective analysis of a prospective cohort of severe TBI patients whose PbtO₂ was monitored. The relationship between Hgb—categorized into four quartiles (≤9; 9–10; 10.1–11; >11 g/dl)—and PbtO₂ was analyzed using mixed-effects models. Anemia with compromised PbtO₂ was defined as episodes of Hgb ≤ 9 g/dl with simultaneous PbtO₂ < 20 mmHg. Outcome was assessed at 30 days using the Glasgow outcome score (GOS), dichotomized as favorable (GOS 4–5) vs. unfavorable (GOS 1–3). Results: We analyzed 474 simultaneous Hgb and PbtO₂ samples from 80 patients (mean age 44 ± 20 years, median GCS 4 (3–7)). Using Hgb > 11 g/dl as the reference level, and controlling for important physiologic covariates (CPP, PaO₂, PaCO₂), Hgb ≤ 9 g/dl was associated with lower PbtO₂ (coefficient −6.53 (95% CI −9.13; −3.94), p < 0.001). Anemia with simultaneous PbtO₂ < 20 mmHg, but not anemia alone, increased the risk of unfavorable outcome (odds ratio 6.24 (95% CI 1.61; 24.22), p = 0.008), controlling for age, GCS, Marshall CT grade, and APACHE II score. Conclusions: In this cohort of severe TBI patients whose PbtO₂ was monitored, a Hgb level no greater than 9 g/dl was associated with compromised PbtO₂. Anemia with simultaneous compromised PbtO₂, but not anemia alone, was a risk factor for unfavorable outcome, irrespective of injury severity.

Keywords Hemoglobin · Brain tissue oxygen tension · Anemia · Traumatic brain injury · Cerebral oxygenation · Clinical study · Humans · Outcome · Brain oxygen · Brain injury

M. Oddo · J. M. Levine · M. Kumar · S. Frangos · E. Maloney-Wilensky · P. D. Le Roux
Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

J. M. Levine · M. Kumar
Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

J. M. Levine · M. Kumar
Department of Anesthesiology and Critical Care, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

M. Oddo (✉)
Department of Intensive Care Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland
e-mail: mauro.oddo@chuv.ch
Tel.: +41-79-5561246

K. Iglesias
Faculty of Biology and Medicine, Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne University Hospital, 1011 Lausanne, Switzerland
Introduction

Anemia is frequent after traumatic brain injury (TBI), occurring in up to 50% of patients [1, 2]. Normally, dilatation of cerebral arterioles augments cerebral blood flow (CBF) and preserves oxygen delivery in the setting of decreased oxygen content associated with anemia [3], therefore symptoms of anemia-induced brain dysfunction become manifest only when hemoglobin (Hgb) is less than 7 g/dl [4, 5]. In conditions of impaired cerebral autoregulation, such as occurs after TBI, compensatory mechanisms may be insufficient to maintain adequate CBF and anemia-induced brain injury may occur at higher Hgb thresholds, e.g., <9–10 g/dl [6]. In animal models of TBI, anemia reduces cerebral oxygenation [4, 7] and aggravates secondary brain injury [7–9]. Anemia also worsens prognosis [10, 11], although the relationship between anemia and TBI prognosis is still controversial [12]. Furthermore, correction of anemia with red blood cell transfusion, particularly when using Hgb targets greater than 10 g/dl, may in turn be associated with increased morbidity [13–15]. Guidelines recommend that anemia should not be the only factor used to decide whether to administer transfusions [16]; however, there are no established physiological markers to guide decision-making in TBI patients with anemia.

In animals, brain tissue oxygen tension (PbtO₂) is a good marker of anemia-induced brain injury [4, 7] and correction of anemia with transfusion [17] is associated with PbtO₂ increase and attenuation of compromised PbtO₂ and injury. Monitoring of PbtO₂ is an established tool to measure cerebral oxygenation in brain-injured patients [18] and is increasingly used in neurocritical care [19]. Cerebral perfusion pressure (CPP) and CBF are important physiologic determinants of PbtO₂ [20, 21]. Other factors include PaO₂ and PaCO₂ [22]. Low PbtO₂ is associated with poor outcome after TBI [23–25]. PbtO₂ might thus provide information about the physiological impact of anemia after severe TBI.

The objective of this study was to investigate the relationship between hemoglobin and PbtO₂ in patients with severe TBI and to examine its impact on outcome.

Materials and methods

Patients

Subjects were part of a prospective database (the brain oxygen monitoring outcome (BOMO) study) that describes patients with severe TBI treated in the neurointensive care unit at the Hospital of the University of Pennsylvania, Philadelphia [23]. Approval for the study was obtained from the institutional review board. Patients included in this study had (1) non-penetrating TBI and (2) both PbtO₂ and intracranial pressure (ICP) monitoring. Patients were excluded who (1) had fixed and dilated pupils at admission, (2) had less than 24 h of intracranial monitoring, (3) had PbtO₂ = 0 mmHg for longer than 3 h, (4) were declared brain dead within 48 h of initiation of monitoring. For the purpose of this study only patients who had at least 24 h of valid PbtO₂ and Hgb sampling were analyzed.

Intracranial monitoring

Intracranial pressure (Camino®, Integra Neurosciences, Plainsboro, NJ) and PbtO₂ (Licox®, Integra Neurosciences) were monitored as part of standard patient care [23, 26]. Monitors were inserted at the bedside into the frontal lobe and secured with a triple-lumen bolt. In all patients, monitors were placed into white matter that appeared normal on the admission head CT. When there was no asymmetry in brain pathology on CT, the probes were placed in the right frontal region. If the patient had undergone a craniotomy, the probes were placed on the same side as the injury if the craniotomy flap permitted. Non-contrast head CT scan was performed in all patients within 24 h of admission to confirm correct placement of the various monitors, e.g., not in a contusion or infarct. Probe function was confirmed by an oxygen challenge (FiO₂ 1.0 for 2 min). To allow for probe equilibration, data from the first 3 h after ICP and PbtO₂ monitor insertion were discarded. Each patient also had an arterial catheter for mean arterial pressure (MAP) recording and calculation of CPP (MAP–ICP).

General clinical management

All patients were managed according to a protocol based on published recommendations for severe TBI care [27]. This included early evacuation of traumatic hematomas, pressure-limited ventilation to maintain PaCO₂ between 30 and 40 mmHg and SaO₂ > 93 %, sedation using propofol during the first 24 h followed by sedation and analgesia using lorazepam, morphine, or fentanyl, bed rest with head elevation initially of at least 30°, euvolemia using 0.9 % normal saline, and anticonvulsant prophylaxis with phenytoin for 1 week. Goals of therapy included maintaining ICP < 20 mmHg and CPP > 60 mmHg.

Elevated ICP (>20 mmHg for longer than 2 min) was initially treated with head of bed elevation, sedation, and analgesia. If ICP remained greater than 20 mmHg for longer than 10 min despite these measures, osmotherapy was administered with mannitol (0.5–1 g/kg, 25 % solution). Thereafter, cerebrospinal fluid was drained using
an external ventricular drain particularly if there was hydrocephalus. Second-tier therapies for refractory intracranial hypertension included optimized hyperventilation (PaCO₂ 30–35 mmHg), decompressive craniectomy, or pharmacological coma (with propofol or pentobarbital).

Management of brain oxygen

Patients received “cause-directed therapy” to maintain PbtO₂ ≥ 20 mmHg according to our local protocol and as previously described [23, 26]. When PbtO₂ was low in the setting of ICP > 20 mmHg, measures were taken to lower ICP as described above. If ICP < 20 mmHg or lowering ICP failed to raise PbtO₂ then CPP was increased with phenylephrine. If the cause of low PbtO₂ was systemic hypoxemia then pulmonary function was optimized (by increasing FiO₂ and/or positive end-expiratory pressure). If excess metabolic demand was suspected (e.g., pain, agitation, fever, or seizures) then analgesic, sedative, or antiepileptic medications were administered. If these measures failed and hemoglobin was less than 10 g/dl a blood transfusion was administered.

Blood transfusion

Hemoglobin concentration was measured at least twice per day and the decision to transfuse blood was based on the discretion of the clinician in charge and the patient’s clinical status when Hgb was 7–10 g/dl. Blood transfusion was given if hemoglobin was less than 7 g/dl. Blood gas concentrations (including PaO₂ and PaCO₂) were measured simultaneously with Hgb concentration.

Outcome assessment

A neurointensivist and a neurocritical nurse independently assessed short-term outcome at 30 days using the Glasgow outcome score (GOS), dichotomized as favorable (GOS 4 = moderate disability or 5 = good recovery) or unfavorable (GOS 1 = death, 2 = vegetative state, and 3 = severe disability requiring long-term rehabilitation).

Data collection and processing

Clinical and radiological variables included age, admission Glasgow coma scale (GCS), APACHE II score, and Marshall CT grade [28, 29]. Marshall CT grade was determined by consensus of a neurointensivist, a neuro-radiologist, and a non-ICU neurologist who were blinded to patient outcome. Data were retrieved electronically via the computerized clinical information system. PbtO₂, ICP, and CPP were monitored continuously at the bedside (component monitoring system M1046-9090C, Hewlett Packard, Andover, MA) and also were recorded usually every 15 min and at least every 30 min in ICU records. For PbtO₂ data, artifacts (e.g., periods related to disconnection of monitoring devices, 1.0 FiO₂ during respiratory therapy), and data points outside of physiological ranges were manually excluded. For each patient, every consecutive hemoglobin sample was matched to simultaneous pressure data: matching was performed by calculating the mean value for PbtO₂, ICP, and CPP recorded over the 3 h preceding the Hgb sampling. Levels of Hgb were categorized into four separate quartiles: >11, 10.1–11, 9.1–10, and ≤9 g/dl. Anemia was defined as the presence of at least one episode of Hgb ≤ 9 g/dl, according to current transfusion practices and Hgb targets for transfusion in neurocritical care [1, 11, 30–32]. Compromised brain oxygen was defined as the presence of at least one episode of PbtO₂ < 20 mmHg for at least 15 min, according to our threshold for therapeutic intervention and the actual definition of moderate brain hypoxia [33] or compromised brain oxygen [34]. Anemia with compromised PbtO₂ was defined as the simultaneous occurrence of episodes with Hgb ≤ 9 g/dl and PbtO₂ < 20 mmHg.

Statistical analysis

Longitudinal data analysis was performed to account for repeated measures of physiological variables across different patients over time. Repeated measures of Hgb and of PbtO₂ were analyzed using a mixed-effects multilevel regression model, with mean PbtO₂ values nested into the patients and Hgb levels (categorized into four quartiles: ≤9, 9.1–10, 10.1–11, >11 g/dl, using >11 g/dl as the level of reference), CPP, PaO₂, PaCO₂, age, Marshall CT grade, admission GCS, APACHE II score (without GCS) as covariates. To examine the risk factors for unfavorable outcome at 30 days a logistic regression was used with age, Marshall CT grade, admission GCS, APACHE II score (without GCS), anemia, compromised PbtO₂, and anemia with simultaneous compromised PbtO₂ Data analysis was performed using STATA 12.0 (College station, Texas, 77845, USA). Significance was defined as p ≤ 0.05.

Results

Patient characteristics

Eighty patients hospitalized over a 4-year period were studied (Table 1). Thirty-one patients managed during the same time period were excluded because of penetrating TBI (n = 10), ICP and PbtO₂ monitoring for less than
Table 1: Patient clinical characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient number</td>
<td>80</td>
</tr>
<tr>
<td>Age (years)</td>
<td>44 ± 20</td>
</tr>
<tr>
<td>Female/male (%)</td>
<td>18/62 (22.5 %)</td>
</tr>
<tr>
<td>Median admission GCS</td>
<td>4 (IQR 3–7)</td>
</tr>
<tr>
<td>Marshall CT grade</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>18 (22 %)</td>
</tr>
<tr>
<td>III</td>
<td>26 (33 %)</td>
</tr>
<tr>
<td>IV</td>
<td>3 (4 %)</td>
</tr>
<tr>
<td>V</td>
<td>33 (41 %)</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>19 ± 5</td>
</tr>
<tr>
<td>Glasgow outcome score (GOS)</td>
<td></td>
</tr>
<tr>
<td>Good outcome GOS (4–5)</td>
<td>49 (61 %)</td>
</tr>
<tr>
<td>Poor outcome GOS (1–3)</td>
<td>31 (39 %)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or median (interquartile range, IQR)

24 h (n = 8), PbtO₂ = 0 mmHg with a confirmed diagnosis of brain death within 48 h of the start of intracranial monitoring (n = 8), and incomplete PbtO₂ data (n = 5). An additional 23 patients were excluded from the present analysis because of lack of data on Hgb or blood gas analysis.

Relationship between hemoglobin and PbtO₂

Monitoring of PbtO₂ started on average 16 h after TBI and lasted for 5 ± 3 days. A total of 474 hemoglobin samples were analyzed. Median hemoglobin concentration was 10 g/dl (range 6.4–15.2 g/dl). Anemia (Hgb ≤ 9 g/dl) was observed in 154 samples (33 %). The median number of Hgb samples per patient was four (IQR 2–6). The majority of Hgb samples were between 9 and 11 g/dl: 13 % of samples were <8 g/dl, 2.5 % were <7 g/dl, 13 % were >12 g/dl, and 4 % were >13 g/dl. Categorization of Hgb into four quartiles (<9, 9.1–10, 10.1–11, >11 g/dl) provided optimal distribution of Hgb samples.

Using a mixed-effects model, estimated mean (95 % CI) PbtO₂ values were calculated for each Hgb level (Fig. 1): compared to Hgb > 11 g/dl (reference level), mean PbtO₂ was lower when Hgb level was ≤9 g/dl (p < 0.001), whereas no significant differences in mean PbtO₂ were found at higher Hgb levels. Association of Hgb with PbtO₂ was further examined after adjusting for CPP, PaO₂, and PaCO₂ (Table 2) and for outcome predictors (age, admission GCS, Marshall CT grade, APACHE II score): compared to Hgb > 11 g/dl, Hgb ≤ 9 g/dl was the only Hgb level that was associated with lower PbtO₂ values (coefficient −6.53 (95 % CI −9.13; −3.94), p < 0.001). A positive linear relationship between PbtO₂ and CPP also was found (coefficient 0.12 (95 % CI 0.04; 0.20), p = 0.003), i.e., for each 10 mmHg decrease of CPP the PbtO₂ was 1.2 mmHg lower.

Mixed-effects multilevel model was used to examine the relationship between mean PbtO₂ and different hemoglobin levels, with values of PbtO₂ nested into patients and quartiles of hemoglobin, cerebral perfusion pressure, PaO₂, PaCO₂, age, admission GCS, Marshall CT grade, and APACHE II score entered as covariates. Compared to hemoglobin >11 g/dl (reference level), a hemoglobin level ≤9 g/dl was associated with lower PbtO₂ levels. A decrease in cerebral perfusion pressure was also associated with a reduction of PbtO₂. All the other covariates did not contribute significantly to the model.

Table 2: Multivariate associations between the different hemoglobin levels and mean PbtO₂

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>95% CI</th>
<th>Adjusted p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin level (g/dl)</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>&gt;11</td>
<td>−0.65</td>
<td>−3.40; 2.09</td>
<td>0.641</td>
</tr>
<tr>
<td>10.1–11</td>
<td>−0.14</td>
<td>−3.13; 2.85</td>
<td>0.929</td>
</tr>
<tr>
<td>9.1–10</td>
<td>−6.53</td>
<td>−9.13; −3.94</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>≤9</td>
<td>−0.02</td>
<td>−0.13; 0.08</td>
<td>0.692</td>
</tr>
<tr>
<td>Cerebral perfusion pressure</td>
<td>0.12</td>
<td>0.04; 0.20</td>
<td>0.003</td>
</tr>
<tr>
<td>PaO₂</td>
<td>0.002</td>
<td>−0.01; 0.01</td>
<td>0.971</td>
</tr>
<tr>
<td>PaCO₂</td>
<td>0.10</td>
<td>−0.03; 0.22</td>
<td>0.120</td>
</tr>
<tr>
<td>Age</td>
<td>−0.02</td>
<td>−0.13; 0.08</td>
<td>0.692</td>
</tr>
<tr>
<td>Admission GCS</td>
<td>0.37</td>
<td>−0.16; 0.89</td>
<td>0.168</td>
</tr>
<tr>
<td>Marshall CT grade</td>
<td>−0.16</td>
<td>−1.71; 1.39</td>
<td>0.839</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>−0.23</td>
<td>−0.79; 0.32</td>
<td>0.409</td>
</tr>
<tr>
<td>Intercept</td>
<td>21.40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mixed-effects multilevel model was used to examine the relationship between mean PbtO₂ and different hemoglobin levels, with values of PbtO₂ nested into patients and quartiles of hemoglobin, cerebral perfusion pressure, PaO₂, PaCO₂, age, admission GCS, Marshall CT grade, and APACHE II score entered as covariates. Compared to hemoglobin >11 g/dl (reference level), a hemoglobin level ≤9 g/dl was associated with lower PbtO₂ levels. A decrease in cerebral perfusion pressure was also associated with a reduction of PbtO₂. All the other covariates did not contribute significantly to the model.

Relationships between unfavorable outcome and anemia, compromised PbtO₂, and anemia with simultaneous compromised PbtO₂

Fifty-three patients (51 %) had anemia and 64 (80 %) had brain hypoxia. Thirty patients had anemia with compromised PbtO₂ (38 %), i.e., they had at least one episode with simultaneous Hgb ≤ 9 g/dl and PbtO₂ < 20 mmHg. Patients without simultaneous anemia and compromised PbtO₂ (n = 50; 62 %) were distributed as followed: six had no anemia and no compromised PbtO₂, ten had anemia alone without compromised PbtO₂, 21 had
Table 3 Relationship between anemia with simultaneous compromised PbtO₂ and unfavorable outcome

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds ratio</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia (Hgb &lt; 9 g/dl) and simultaneous brain hypoxia (PbtO₂ &lt; 20 mmHg)</td>
<td>6.24</td>
<td>1.61; 24.22</td>
<td>0.008</td>
</tr>
<tr>
<td>Admission GCS</td>
<td>0.80</td>
<td>0.65; 1.00</td>
<td>0.045</td>
</tr>
<tr>
<td>Marshall CT grade</td>
<td>1.69</td>
<td>0.98; 2.93</td>
<td>0.059</td>
</tr>
<tr>
<td>APACHE II score</td>
<td>1.27</td>
<td>1.02; 1.58</td>
<td>0.030</td>
</tr>
<tr>
<td>Age</td>
<td>1.01</td>
<td>0.97; 1.04</td>
<td>0.758</td>
</tr>
</tbody>
</table>

Logistic regression was used to examine the association between anemia with simultaneous brain hypoxia and unfavorable outcome (defined as a GCS 1–3 at 30 days), adjusting for age, admission GCS, Marshall CT grade, and APACHE II score. The presence of anemia with simultaneous brain hypoxia increased the risk of unfavorable outcome by 6.24. Sensitivity of the model was 74 %, specificity 86 %, and the area under the ROC curve 0.88.

compromised PbtO₂ alone without anemia, and 13 had anemia and compromised PbtO₂ that did not occur simultaneously. After adjusting for age, admission GCS, Marshall CT grade, and APACHE II score, anemia with simultaneous compromised PbtO₂ increased the risk of unfavorable outcome (adjusted odds ratio 6.24 (95 % CI 1.61; 24.22), p = 0.008) (Table 3). Sensitivity of the model was 74 %, specificity 86 %, and area under the ROC curve 0.88.

When the number of red blood cell transfusions received (complete data available on 57/80 patients) was added as a covariate to the model, the association between anemia with simultaneous compromised PbtO₂ and 30-day outcome remained significant (adjusted odds ratio 8.50 (95 % CI 1.22; 59.49), p = 0.031).

Entering anemia and compromised PbtO₂ separately as two variables in the model instead of anemia with simultaneous compromised PbtO₂ shows no impact of having Hgb ≤ 9 vs. > 9 g/dl on unfavorable outcome (adjusted OR 0.89 (95 % CI 0.23; 3.51), p = 0.867), whereas having at least one episode of PbtO₂ < 20 mmHg vs. no compromised PbtO₂ increased the risk of unfavorable outcome (adjusted OR 9.42, 95 % CI (1.49–59.63), p = 0.017).

Impact of anemia with compromised PbtO₂ on unfavorable outcome

Anemia is observed in approximately 50 % of TBI patients [2]. Whether anemia is associated with poor outcome after TBI is still controversial: some studies found that anemia during the ICU stay was associated with worse prognosis [10, 11], but another did not [12]. A possible explanation for these controversial findings is that the vulnerability of the brain to anemia may differ across TBI patients. An important mechanism by which anemia may contribute to secondary cerebral damage is by reducing oxygen transport capacity and PbtO₂ [9]. Consistent with this are the findings of increased expression of hypoxia-related molecules (erythropoietin, endothelial derived factors, neuronal nitric oxide synthase) [8], providing mechanistic evidence of anemia-induced tissue hypoxia. Here, we show that the simultaneous occurrence of anemia and compromised PbtO₂ was associated with worse outcome at 30 days. In contrast, we found no association between anemia alone and outcome. This is an important and novel finding that suggests that anemia per se may not be detrimental, but it may aggravate prognosis when it is simultaneously associated with compromised PbtO₂. Importantly, when adjusting for the number of units of blood transfused, the association of anemia and simultaneous compromised PbtO₂ with outcome remained statistically significant, suggesting that...

Discussion

In our cohort of 80 severe TBI patients whose intraparenchymal PbtO₂ was monitored, we found a significant relationship between Hgb and PbtO₂, whereby an Hgb level ≤ 9 g/dl was strongly associated with lower mean PbtO₂ values. Also, anemia (defined as Hgb ≤ 9 g/dl) and simultaneous compromised PbtO₂ (defined as PbtO₂ < 20 mmHg), but not anemia alone, was associated with a higher risk of unfavorable outcome, irrespective of cerebral and systemic injury, and even after controlling for the amount of blood that was transfused.

Relationship between hemoglobin and brain oxygen

Studies in TBI patients have used variable thresholds (8–11 g/dl) to define anemia [1, 2], but an optimal threshold for the definition of anemia in this setting is still unknown. From a physiological standpoint, the lowest Hgb threshold can be defined as the Hgb level below which oxygen delivery is impaired and cerebral hypoxic injury begins to occur. Mathematical modeling in animals suggests that oxygen uptake in the ischemic brain progressively decreases when hemoglobin concentration is less than 10 g/dl [6]. Here, we found mean PbtO₂ values were lower when hemoglobin was no greater than 9 g/dl. After adjusting for important determinants of cerebral oxygenation (CPP, PaO₂, and PaCO₂) and outcome (age, GCS, Marshall CT grade, APACHE II score), Hgb ≤ 9 g/dl was the only Hgb level that was associated with significantly lower PbtO₂. This Hgb threshold is in line with the definition of anemia utilized by the largest TBI prognostic database (the MRC CRASH trial, including more than 8,500 patients) [32] and with the current Hgb targets for blood transfusion in neurocritical care [1, 11, 30, 31].
anemia with compromised PbO$_2$ per se, independent of transfusions, was a risk factor for unfavorable outcome.

Potential clinical implications of our study

Understanding the mechanisms involved in anemia-induced cerebral injury will contribute to the development of optimal therapy for anemic TBI patients. An important issue is a clearer definition of transfusion triggers based on individual physiological endpoints rather than generalized hemoglobin thresholds: this may reduce transfusion-related morbidity and attenuate anemia-induced cerebral insults, i.e., balance the potential risks associated with anemia and transfusion [16]. Our findings suggest that PbO$_2$ may be a useful physiological target to manage anemia in patients with severe TBI.

Study limitations

There are several potential limitations to our study. First, although data were extracted prospectively, analysis was retrospective. However statistical analysis was performed by an independent statistician (Katia Iglesias) and blinded to patient outcome. Second, despite a standardized algorithm to manage ICP/CPP/PbO$_2$ being applied to all subjects, the study was performed at a single institution and included a limited sample size and a selected group of severe TBI patients who underwent PbO$_2$ monitoring. Our findings cannot be generalized to a wider TBI population: larger studies are needed to confirm our findings. All patients received cause-directed therapy to maintain PbO$_2$ > 20 mmHg: therefore it is possible that patients with anemia and low PbO$_2$ were those who were unresponsive to interventions to ‘correct’ compromised PbO$_2$ and that this was a failure of PbO$_2$ to respond to interventions that drove this outcome. This is a potential confounder. Third, Hgb values were matched to values of PbO$_2$, CPP, and blood gas analysis obtained during the 3 h previous to Hgb sampling. Although somewhat arbitrary we found this interval appropriate, particularly because we did not account for concomitant therapeutic interventions that may substantially alter many of the variables measured. Increasing this interval further (e.g., up to 12 h) could have introduced confounding factors. On the other hand, the relationship between hemoglobin, PbO)$_2$, and outcome may have been underestimated. Another important issue is whether the covariation between PbO$_2$, Hgb, and outcome are interlinked due to other reasons: owing to the nature of the study, this cannot be determined. Furthermore, given the limited number of samples with Hgb < 8 and < 7 g/dl, the relevance of the proportion of patients with Hgb thresholds lower than 9 g/dl is unclear. Fourth, only outcome at 30 days was obtained: although this time point may be sufficient to differentiate outcomes of general ICU patients, it may not be sufficient time to reflect long-term recovery. Thus we cannot speculate as to whether anemia with compromised PbO$_2$ is associated with worse long-term prognosis. Fifth, the PbO$_2$ monitor measures regional PbO$_2$: clinical studies suggest that regional PbO$_2$ still may be a good indicator of global brain oxygenation, particularly when the probe is located in uninjured brain [35] as in the present study. Since the PbO$_2$ probes were placed in normal-appearing brain tissue on admission CT, and not around areas of contusions or lesions, it may underestimate the extent of brain hypoxia, at least in patients with focal injuries and hematomas [33]. Sixth, the precise causes of anemia-related brain hypoxia in our TBI cohort are not defined. Mixed-effects models, however, indicate that low CPP was an important cause of reduced PbO$_2$. Finally, logistic regression model performed on the subset of patients in whom complete data on blood transfusions were available ($n$ = 5780) showed that the impact of anemia with compromised PbO$_2$ was independent of the units of blood transfused. Although this result was derived from a rather limited number of patients, it reinforces the main conclusions of the study.

Conclusions

In this cohort study of severe TBI patients whose brain oxygen was monitored, patients with hemoglobin levels no greater than 9 g/dl were more likely to have lower mean PbO$_2$ values, irrespective of other important physiologic cofactors, including cerebral perfusion pressure, PaO$_2$, and PaCO$_2$. Anemia with simultaneous compromised PbO$_2$, but not anemia alone, increased the risk of unfavorable 30-day outcome after severe TBI. Our findings suggest that anemia-associated compromised PbO$_2$ may aggravate TBI prognosis and support the concept that PbO$_2$ may be a helpful physiologic target for the management of anemia after severe head injury.

Acknowledgments Supported by grants from the Swiss National Science Foundation (grant no. 320030_138191) and the European Society of Intensive Care Medicine (ECCRN Clinical Research Award 2010) (to M.O.), and the Integra Foundation and the Mary Elisabeth Groff Surgical and Medical Research Trust (to P.D.L.).

Conflicts of interest Eileen Maloney-Wilensky and Peter D. LeRoux are members of Integra Lifesciences Speaker’s Bureau. Integra Lifesciences, however, had no involvement of any kind in the present study.
References


